Stock CSL CSL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials CSL Limited

Equities

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E.
Other stock markets
 02:10:45 2024-04-26 EDT 		5-day change 1st Jan Change
273.3 AUD -1.85% Intraday chart for CSL Limited +1.41% -4.66%
04-26 Australian shares tumble as miners, energy stocks fall; BHP Group tanks RE
04-24 CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy CI

Valuation

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 68,373 89,914 97,314 89,378 89,111 86,131 - -
Enterprise Value (EV) 1 72,378 94,712 101,308 88,599 99,790 95,958 94,800 93,319
P/E ratio 35.7 x 42.9 x 41 x 38.7 x 40.8 x 31.5 x 26.2 x 22.5 x
Yield 1.23% 1.02% 1.04% 1.2% 1.28% 1.49% 1.74% 2%
Capitalization / Revenue 8.01 x 9.83 x 9.44 x 8.46 x 6.7 x 5.85 x 5.4 x 5.03 x
EV / Revenue 8.48 x 10.4 x 9.83 x 8.39 x 7.5 x 6.52 x 5.94 x 5.45 x
EV / EBITDA 25.1 x 30.2 x 27.2 x 24.6 x 25.6 x 19.6 x 17.3 x 15 x
EV / FCF 137 x 73.9 x 41.8 x 57.2 x 72.7 x 43.9 x 32.7 x 25.9 x
FCF Yield 0.73% 1.35% 2.39% 1.75% 1.38% 2.28% 3.05% 3.87%
Price to Book 13 x 13.8 x 11.6 x 6.13 x 5.64 x 4.81 x 4.35 x 3.91 x
Nbr of stocks (in thousands) 453,139 454,049 455,126 481,706 482,372 483,253 - -
Reference price 2 150.9 198.0 213.8 185.5 184.7 178.2 178.2 178.2
Announcement Date 19-08-13 20-08-18 21-08-17 22-08-16 23-08-14 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 8,539 9,151 10,310 10,562 13,310 14,723 15,948 17,124
EBITDA 1 2,879 3,136 3,720 3,596 3,900 4,907 5,490 6,206
EBIT 1 2,504 2,716 3,130 2,927 3,069 4,222 4,768 5,460
Operating Margin 29.33% 29.69% 30.36% 27.72% 23.06% 28.68% 29.89% 31.89%
Earnings before Tax (EBT) 1 2,341 2,573 2,963 2,780 2,663 3,621 4,277 4,969
Net income 1 1,919 2,102 2,375 2,255 2,194 2,712 3,264 3,788
Net margin 22.47% 22.98% 23.04% 21.35% 16.48% 18.42% 20.47% 22.12%
EPS 2 4.226 4.615 5.210 4.800 4.530 5.657 6.801 7.909
Free Cash Flow 1 526.8 1,282 2,426 1,550 1,373 2,185 2,896 3,607
FCF margin 6.17% 14% 23.53% 14.67% 10.32% 14.84% 18.16% 21.07%
FCF Conversion (EBITDA) 18.3% 40.86% 65.21% 43.1% 35.21% 44.53% 52.75% 58.12%
FCF Conversion (Net income) 27.46% 60.95% 102.13% 68.74% 62.58% 80.55% 88.72% 95.24%
Dividend per Share 2 1.850 2.020 2.220 2.220 2.360 2.657 3.097 3.560
Announcement Date 19-08-13 20-08-18 21-08-17 22-08-16 23-08-14 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 4,911 4,240 5,739 4,571 6,041 4,521 7,184 6,126 8,053 6,656
EBITDA 1 1,836 1,300 2,638 1,081 2,479 1,117 2,516 1,384 3,042 2,146
EBIT 1 1,632 1,084 2,358 772 2,215 712.7 2,134 934.7 2,795 1,551
Operating Margin 33.23% 25.58% 41.09% 16.89% 36.67% 15.77% 29.71% 15.26% 34.71% 23.3%
Earnings before Tax (EBT) 1,561 1,011 2,251 712.1 2,145 635.2 1,963 - 2,379 -
Net income 1 1,248 854.5 1,810 565 1,760 494.4 1,623 570.8 1,901 781.5
Net margin 25.41% 20.15% 31.54% 12.36% 29.13% 10.94% 22.6% 9.32% 23.61% 11.74%
EPS 2.740 1.875 3.980 1.230 3.850 0.9600 3.370 - 3.920 -
Dividend per Share 2 0.9500 1.070 1.040 1.180 1.040 1.180 1.070 1.290 1.190 1.360
Announcement Date 20-02-11 20-08-18 21-02-17 21-08-17 22-02-15 22-08-16 23-02-13 23-08-14 24-02-12 -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 4,005 4,798 3,993 - 10,679 9,827 8,669 7,188
Net Cash position 1 - - - 779 - - - -
Leverage (Debt/EBITDA) 1.391 x 1.53 x 1.074 x - 2.738 x 2.003 x 1.579 x 1.158 x
Free Cash Flow 1 527 1,282 2,426 1,550 1,373 2,185 2,896 3,607
ROE (net income / shareholders' equity) 41.1% 35.7% 31.9% 19.6% 14.5% 17.2% 18% 19%
ROA (Net income/ Total Assets) 16.6% 15.1% 14.1% 9.7% 6.79% 8.79% 9.78% 10.7%
Assets 1 11,544 13,890 16,886 23,252 32,290 30,861 33,376 35,495
Book Value Per Share 2 11.60 14.40 18.40 30.30 32.70 37.10 41.00 45.60
Cash Flow per Share 2 3.620 5.460 7.940 5.590 5.380 5.950 7.840 9.660
Capex 1 1,118 1,207 1,196 1,079 1,228 877 982 1,028
Capex / Sales 13.09% 13.19% 11.6% 10.21% 9.23% 5.96% 6.16% 6%
Announcement Date 19-08-13 20-08-18 21-08-17 22-08-16 23-08-14 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for CSL Limited

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
178.2 USD
Average target price
199.4 USD
Spread / Average Target
+11.88%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-8.42% 8.12B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. CSL Stock
  4. Financials CSL Limited